Analystreport

Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA) had its "buy" rating re-affirmed by analysts at Brookline Capital Management.

Hepion Pharmaceuticals, Inc.  (HEPA) 
Last hepion pharmaceuticals, inc. earnings: 11/14 05:17 pm Check Earnings Report